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MaBACKGROUND The American College of Cardiology (ACC) and the American Heart Association (AHA) have been
developing clinical guidelines to assist practicing clinicians.
OBJECTIVES The goal of this study was to evaluate changes in ACC/AHA guideline recommendations between 2008
and 2014.
METHODS The previous and current ACC/AHA guideline documents that were updated between 2008 and June 2014
were compared to determine changes in Class of Recommendation (COR) and Level of Evidence (LOE). Each recom-
mendation was classiﬁed as new, dropped, revised, or unchanged, and the changes in evidence were examined.
RESULTS During the study period, 11 guideline documents (9 disease based and 2 interventional procedure based) were
updated. The total number of recommendations decreased from 2,067 to 1,869 (321 fewer recommendations in disease-
based guidelines and 123 additional recommendations in interventional procedure–based guidelines). The recommenda-
tion class distribution of the updated guidelines was 50.1% Class I (previously 50.8%), 39.4% Class II (previously 35.4%),
and 10.4% Class III (previously 13.8%) (p ¼ 0.001). The LOE distribution among updated versions was 15.0% for LOE: A
(previously 13.3%), 50.8% for LOE: B (previously 41.4%), and 34.2% for LOE C (previously 45.3%) (p< 0.001). Among all
guidelines, 859 recommendations were new, 1,339 were dropped, 881 were unchanged in COR and LOE, and 129 were
revised. Of the revised guidelines, 75 recommendations had an increase in LOE (the majority from LOE: C to LOE: B);
34 recommendations had a decrease in LOE; and 20 recommendations had class changes. LOE increases were justiﬁed by
introduction of new randomized controlled trials, new studies, and new meta-analyses.
CONCLUSIONS The ACC/AHA guideline recommendations are undergoing signiﬁcant changes, becoming more
evidence based and scientiﬁcally robust with a tendency to exclude recommendations with insufﬁcient scientiﬁc evidence.
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AB BR E V I A T I O N S
AND ACRONYM S
ACC = American College of
Cardiology
AHA = American Heart
Association
CABG = coronary artery
bypass graft
COR = Class of
Recommendation
LOE = Level of Evidence
NSTEMI = non–ST-segment
elevation myocardial infarction
PCI = percutaneous coronary
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2727guidelines offer a benchmark that can be used to mea-
sure and compare quality of care and disease
outcomes.
In 2009, Tricoci et al. (1) published a systematic
review of the ACC/AHA guidelines and their evolu-
tion over time. They reported that the guidelines
had “largely developed from lower levels of evi-
dence or expert opinion” and that the “proportion of
recommendations for which there was no conclusive
evidence was growing.” Six years later, many
guidelines have been updated. We performed a
detailed analysis of the original and updated guide-
lines to determine the extent and types of interim
changes.TABLE 1 Year of Publication of the Previous and the Most
Up-To-Date Clinical Guidelines Included in the Present Study
Previous
(Year)
Updated
(Year)
Type of
Update
Atrial ﬁbrillation (2,3) 2006 2014 Full
Heart failure (4,5) 2005 2013 Full
Stable ischemic heart disease (14,15) 2002 2012 Full
Valvular heart disease (16,17) 2008 2014 Full
STEMI (18,19) 2004 2013 Full
PCI (20,21) 2005 2011 Full
CABG (22,23) 2004 2011 Full
Peripheral arterial disease (6,7) 2005 2011 Focused
Perioperative evaluation (8,9) 2007 2009 Focused
Secondary prevention (10,11) 2006 2011 Focused
Unstable angina/NSTEMI (12,13) 2007 2012 Focused
CABG ¼ coronary artery bypass graft; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼
ST-segment elevation myocardial infarction.
SEE PAGE 2735
intervention
STEMI = ST-segment elevation
myocardial infarctionMETHODS
SOURCE OF MATER IALS . All ACC/AHA guidelines
were downloaded from the ACC website on June 10,
2014, and guidelines that changed between 2008
and 2014 were identiﬁed. Both full guideline re-
visions and focused updates were included in the
present analysis. The Level of Evidence (LOE) and
Class of Recommendation (COR) classiﬁcation were
abstracted. The total number of recommendations
within each recommendation class and the distribu-
tion of LOE designations across all recommendations
were evaluated.
COMPARISONS. The most current guidelines were
compared with those studied by Tricoci et al. (1) in
2009. Focused updates to guidelines were consid-
ered in the context of additional guidelines incor-
porated into the full guidelines. All guidelines were
classiﬁed as disease based or interventional proce-
dure based (there were no changes in diagnostic
procedure–based guidelines between 2008 and
2014). For each guideline, the number of recom-
mendations, as well as the COR and the LOE for each
recommendation, were compared between the pre-
vious and the most current version. Each recom-
mendation in the current guidelines was categorized
as new, dropped, unchanged, or revised. Revised
recommendations were further classiﬁed according
to COR and LOE change. In addition, the reason for
each change, such as new clinical data, was
investigated.
The distribution of COR and LOE was compared by
using the chi-square test with a Yates’ correction.
A p value <0.05 was considered statistically signiﬁ-
cant. All analyses were performed by using JMP ver-
sion 11.0 (SAS Institute, Inc., Cary, North Carolina).RESULTS
GUIDELINE CHANGES. Nine disease-based
guidelines were analyzed: atrial ﬁbrillation
(2,3), heart failure (4,5), peripheral arterial
disease (6,7), perioperative evaluation (8,9),
secondary prevention (10,11), unstable angina
and non–ST-segment elevation myocardial
infarction (NSTEMI) (12,13), stable ischemic
heart disease (14,15), valvular heart disease
(16,17), and ST-segment elevation myocardial
infarction (STEMI) (18,19). In addition, 2
interventional procedure–based guidelines
were assessed: percutaneous coronary inter-
vention (PCI) (20,21) and coronary artery
bypass graft (CABG) (22,23) (Table 1, Figure 1).
The time interval between publication of the
previous and the current updated version of each
guideline was 6.5  2.5 years for the disease-based
guidelines and 6.5  0.7 years for the interventional
procedure–based guidelines. Author retention varied
widely among the various guideline updates, from 0%
(PCI guidelines) to 80% (perioperative evaluation
guidelines).
NUMBER OF RECOMMENDATIONS. Overall, the total
number of recommendations decreased from 2,067 to
1,869 (Table 2). The recommendations included in the
9 disease-based guidelines decreased by 321 (from
1,847 to 1,526) (Figure 1), whereas those included in
the 2 interventional procedure–based guidelines
increased by 123 (from 220 to 353). The number of
recommendations increased in the updated versions
of the following guidelines: atrial ﬁbrillation, heart
failure, peripheral arterial disease, perioperative
evaluation, secondary prevention, unstable angina
FIGURE 1 Guideline Recommendations
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(A) Therewas a decrease in the total number of recommendations included in the 11 guidelines
updated between 2008 and 2014. The number of recommendations increased in the inter-
ventional procedure–based guidelines but decreased in the disease-based guidelines. (B) The
time interval between publication of the previous and the current updated version of each
guideline was 6.5  2.5 years for disease-based guidelines and 6.5  0.7 years for interven-
tional procedure–based guidelines. CABG¼ coronary artery bypass graft; PCI¼ percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
TABLE 2 Number of Recommendations Within Each Version of the Guidelines
No. of Previous
Guidelines
No. of Current
Guidelines Change
Atrial ﬁbrillation 111 112 1
Heart failure 129 139 10
Peripheral arterial disease 235 246 11
Perioperative evaluation 50 63 13
Secondary prevention 48 67 19
Unstable angina/NSTEMI 297 386 89
Stable ischemic heart disease 235 160 –75
Valvular heart disease 320 231 –89
STEMI 422 122 –300
PCI 136 180 44
CABG 84 163 79
Total 2,067 1,869 –198
Abbreviations as in Table 1.
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2728and NSTEMI, PCI, and CABG. It decreased in the sta-
ble ischemic heart disease, valvular heart disease,
and STEMI guidelines (Figure 2, Table 2).
CLASS OF RECOMMENDATION. In both the earlier
and the updated guidelines, the Class I category
had the most recommendations overall, followed by
Class II and then Class III. Most recommendations
were Class I for disease-based guidelines and
Class II for interventional procedure–based guide-
lines (Figure 3). There was a signiﬁcant change in the
number and COR distribution of guideline recom-
mendations between 2008 and 2014 (p ¼ 0.001)
(Table 3). The greatest change was observed in
Class III recommendations (32% decrease), followed
by Class I (11% decrease), and then Class II (1% in-
crease) recommendations.
LEVEL OF EVIDENCE. The majority of recommenda-
tions in both the disease-based and the interventional
procedure–based guidelines were LOE: B (Table 3,
Figure 3). In the updated guidelines, the number of
LOE: C recommendations decreased by 298 (32%), the
number of LOE: B recommendations increased by
94 (11%), and the number of LOE: A recommendations
increased by 6 (2%). Overall, a signiﬁcant change in
recommendation LOE distribution was observed
between 2008 and 2014 (p < 0.001).
COR AND LOE. Considering COR and LOE together,
the majority of Class I and II recommendations in the
updated guidelines were LOE: B, whereas most
Class III recommendations were LOE: C (Table 4,
Figure 3). Across all 3 classes, the number of LOE: C
recommendations decreased. Class I had the highest
number of LOE: A and LOE: B recommendations. In
the interventional procedure–based guidelines, LOE B
recommendations increased among all 3 COR classes
(Central Illustration).
TEMPORAL TRENDS. Between 2008 and 2011, the
overall number of recommendations increased across
all COR and LOE categories, with the greatest increase
observed in Class II (by 51%) and LOE: C (by 37%)
recommendations. In contrast, between 2012 and
2014, the number of recommendations decreased
across all COR and LOE categories, with the most
pronounced decrease in Class III (by 46%) and LOE: C
(by 46%) recommendations. These ﬁndings remained
consistent after excluding focused updates and the
STEMI guidelines (the most extensively revised).
TYPE OF CHANGE. Each recommendation was
analyzed individually to determine if it was new,
dropped, unchanged, or revised (Tables 5 and 6).
Overall, 1,339 recommendations were dropped, and
859 new recommendations were added. In total, 881
FIGURE 2 Changes in Number of Recommendations Among Guidelines Updated
Between 2008 and 2014
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FIGURE 3 Change in Class of Recommendation and Level of Evidence
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Signiﬁcant increases were observed in Class II and in Level of Evidence: B rec-
ommendations, with concomitant decreases in Class III and Level of Evidence: C
in most guidelines examined.
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2729recommendations were unchanged, and 129 recom-
mendations were revised. The major reason for the
evidence increase was the publication of new studies,
such as randomized controlled trials and meta-
analyses. The LOE decreased in some recommenda-
tions of the revised guidelines because the results of
newer studies contradicted previous recommenda-
tions or new writing group members re-evaluated the
previous evidence. In total, 75 recommendations
had an LOE increase: 51 increased from C to B, 23
increased from B to A and one increased from C to A. In
contrast, 34 recommendations had an LOE decrease,
with most recommendations changing from B to C.
The majority of LOE: C to LOE: B updates were
due to evidence resulting from at least 1 new study
or trial that was completed between 2008 and 2014.
In total, increased LOE was due to new evidence
from observational studies in 34 recommendations
and due to new randomized controlled trials in 17
recommendations. New meta-analyses resulted in
evidence increases from B to A in 10 recommenda-
tions. Five recommendations involved increased
evidence due to new drug studies/trials, and 5 rec-
ommendations involved increased evidence attrib-
uted to changed wording and/or content (e.g.,
simplifying the recommendation). Finally, 3 recom-
mendations were changed on the basis of evidence
from older studies.
DISCUSSION
The major ﬁndings of our study regarding the
updated guidelines are that: 1) the total number of
recommendations decreased; 2) the number of Class I
and III recommendations decreased, and the number
of Class II recommendations increased; and 3) the
number of LOE: A and LOE: B recommendations
increased, whereas the number of LOE C recommen-
dations decreased (Central Illustration).
According to the Institute of Medicine, “clinical
practice guidelines are statements that include rec-
ommendations intended to optimize patient care
that are informed by a systematic review of the
evidence and an assessment of the beneﬁts and
harms of alternative care options” (24). In response to
the Institute of Medicine’s recommendations, the
American College of Cardiology Foundation and the
AHA recently updated the guideline development
methods to include patient representatives, intro-
duce evidence review committees, implement stan-
dardized protocols for systematic review, address
intellectual and clinical practice perspectives and
relations with industry, and expand the guideline
review process (25). These changes likely underpin, at
TABLE 3 Number of Recommendations Included in the Initial and Updated
Guideline Versions, Classiﬁed According to Class of Recommendation and
Level of Evidence
No./Total
Class of
Recommendation
Level
of Evidence
I II III A B C
Disease-based guidelines 5
Year: 2008 973 629 245 243 749 855
Year: 2014 816 561 149* 241 763 522†
Interventional procedure–based
guidelines
Year: 2008 78 103 39 31 107 82
Year: 2014 121 176 46‡ 39 187 117†
Overall totals
Year: 2008 1,051 731 285 274 856 937
Year: 2014 937 737 195§ 280 950 639†
The p values for comparing the distribution of Class of Recommendation and Level of Evidence
between the 2008 and the 2014 guidelines are as follows: *p ¼ 0.005; †p < 0.001; ‡p ¼ 0.33;
§p ¼ 0.001.
TABLE 4 Distributio
Guidelines, Classiﬁed
Disease-based guidelin
Year: 2008
Year: 2014
Interventional procedu
guidelines
Year: 2008
Year: 2014
Overall totals
Year: 2008
Year: 2014
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2730least in part, the guideline recommendation changes
observed in our study.
NUMBER OF RECOMMENDATIONS. The updated guide-
lines included fewer recommendations compared
with the earlier versions: 1,339 recommendations
were removed, and 859 were added. Changes were
more prominent in some guidelines; for example, the
updated STEMI guidelines removed 397 recommen-
dations, while only adding 92. The number of recom-
mendations also signiﬁcantly decreased in the stable
ischemic heart disease and valvular heart disease
guidelines, whereas it increased in the PCI and CABG
guidelines (Table 6). This adding and removing
pattern was observed among all fully updated guide-
lines, in which the authors elected to remove and
rewrite many of the older recommendations instead of
revising them. The numerous changes in guideline
recommendations highlight the signiﬁcant effort
that went into their development. The increase in then of Class of Recommendation and Level of Evidence Among
as Disease Based and Interventional Procedure Based
Class of Recommendation–Level of Evidence
I-A I-B I-C II-A II-B II-C III-A III-B III-C
es
187 414 372 28 264 337 28 71 146
196 388 232 27 316 218 18 59 72
re–based
26 43 9 5 53 45 0 11 28
24 66 31 11 101 64 4 20 22
213 457 381 33 317 382 28 82 174
220 454 263 38 417 282 22 79 94number of recommendations in the updated inter-
ventional procedure–based guidelines is likely due
to recent clinical trial results and advances in devices
and techniques. Moreover, the observed heterogene-
ity in guideline recommendation changes may be the
result of the guideline update type (focused updates
address only speciﬁc areas with new scientiﬁc evi-
dence, whereas complete revisions address a much
broader topic), the year of publication (the number
of recommendations increased in earlier updates,
whereas it decreased in more recent ones, especially
for Class III and LOE: C recommendations), and the
implementation of process improvement initiatives by
the guideline-developing organizations (e.g., imple-
mentation of consensus conferences to reach agree-
ment and involvement of lay representatives) (26).
CLASS OF RECOMMENDATION. Quantitatively, the
number of Class I and Class III recommendations
decreased, whereas the number of Class II recom-
mendations increased. However, taking into account
the decrease in number of recommendations, the
actual proportion of Class I recommendations largely
remained unchanged. The proportion of Class II rec-
ommendations increased, and the proportion of
Class III recommendations decreased, likely due to
the uncertainty of risk versus beneﬁt analyses for
many treatments/procedures.
LEVEL OF EVIDENCE. The decrease of LOE: C rec-
ommendations suggests an effort to focus the guide-
lines into areas with scientiﬁc evidence to support
them, instead of just expert opinion. The changes
observed in our study are consistent with the
ACC/AHA Guidelines Task Force guidance to address
the concern about coupling the strong COR categories
I and III with lower LOEs or expert opinion: “Class I
recommendations based only on LOE: C/E should be
minimized, and Class III: No Beneﬁt recommenda-
tions should be avoided whenever possible if sup-
ported only by LOE: C/E” (26).
Moreover, the increase in LOE: B recommenda-
tions illustrates that there is more evidence-based
medicine being practiced, supported by clinical
studies. This ﬁnding is especially prominent in the
interventional procedure–based guidelines, which
displayed an increase in LOE: B recommendations in
all 3 COR classes. The number of LOE recommenda-
tions increased in the stable ischemic heart disease,
secondary prevention, and valvular heart disease
guidelines but did not signiﬁcantly change when all
guidelines were considered (Table 3).
Comparatively, the previous guidelines study by
Tricoci et al. (1) found that the majority of the rec-
ommendations for ACC/AHA guidelines were on the
CENTRAL ILLUSTRATION Changes in Class of Recommendation and Level of Evidence Across All ACC/AHA
Guideline Recommendations Between 2008 and 2014
Han, H. et al. J Am Coll Cardiol. 2015; 65(25):2726–34.
Overall, Class II recommendations increased and Class III recommendations decreased, as did the proportion of Class C recommendations.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association.
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TABLE 5 Change in Recommendation Level of Evidence Between the Initial and Updated Guidelines
Total No. of
Revised
Recommendations
No. of Revised
Evidence
Recommendations
Evidence Increase Evidence Decrease
B/ A C/ B C/ A A / B B/ C
Atrial ﬁbrillation 14 8 2 3 0 2 1
Heart failure 15 12 3 5 0 1 3
Stable ischemic heart disease 15 13 3 7 0 2 1
STEMI 17 11 1 4 0 4 2
Valvular heart disease 36 33 2 25 1 0 5
Perioperative evaluation 1 1 0 0 0 0 1
Peripheral arterial disease 6 6 2 2 0 1 1
Secondary prevention 12 10 6 1 0 0 3
Unstable angina/NSTEMI* 0 0 0 0 0 0 0
PCI 13 11 2 4 0 1 4
CABG 7 4 2 0 0 0 2
Total 136 109 23 51 1 11 23
*Focused update that added recommendations but did not change the Class of Recommendation and Level of Evidence of earlier recommendations.
Abbreviations as in Table 1.
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2732basis of lower levels of evidence, despite an increased
total number of recommendations across the 12
guidelines that were compared in their study. This
outcome was echoed in the present study, as the
number of LOE: B recommendations slightly in-
creased but the number of LOE: A recommendations
remained largely unchanged.
Although the observed changes in COR and LOE
guidelines demonstrate improving scientiﬁc rigor, a
recent survey of 206 cardiologists found that “more
than two-thirds indicated that the weaker class/levels
were helpful or very helpful when making informed
diagnostic and therapeutic decisions” (26). In other
words, physicians taking care of patients need
guidance on important topics, even when the un-
derlying scientiﬁc evidence is weak. Balancing the
inherent tension between the clinicians’ need forTABLE 6 Change in Individual Recommendations Within Each
Guideline Document
Dropped New Unchanged Revised
Atrial ﬁbrillation 76 45 53 14
Heart failure 86 90 34 15
Stable ischemic heart disease 151 114 31 15
STEMI 397 92 13 17
Valvular heart disease 226 141 54 36
PCI 107 139 35 6
CABG 54 131 25 7
Perioperative evaluation 0 2 60 1
Peripheral arterial disease 3 11 229 6
Secondary prevention 12 30 25 12
Unstable angina/NSTEMI 2 64 322 0
Total 1,339 859 881 129
Abbreviations as in Table 1.comprehensive clinical guidelines and the need to
increase the scientiﬁc robustness of the guidelines is
the subject of continuous evaluation.
CHANGE IN GUIDELINE RECOMMENDATIONS. Table 5
and Online Tables 1 to 3 demonstrate how the LOE
changed within each individual guideline. The
valvular heart disease guideline had the highest
number of revised recommendations (n¼ 33), whereas
the unstable angina/NSTEMI guideline had no changes
in guidelines that carried over, likely because it was a
focused update. The valvular heart disease guideline
accounted for nearly one-half of all the LOE: C to
LOE: B increases and exhibited the most number of
recommendations (n ¼ 28) with any LOE increase. The
secondary prevention guideline had the most recom-
mendations, with increases from LOE: B to LOE: A
(n ¼ 6) that accounted for more than one-quarter of all
LOE: B to LOE: A changes. The LOE decreased from B to
C in twice as many recommendations as from A to B.
Limited author retention could have played a
role in the extensive changes performed in the PCI
(0% retention) and CABG (8.7% retention) guidelines.
However, author retention was relatively high in the
valvular heart disease guidelines (40%), which also
underwent extensive revision. Focused updates
increased the number of recommendations, as well as
the COR and LOE, whereas the number of recom-
mendations decreased in full updates, as did the COR
and LOE: A and LOE: C (whereas the number of LOE: B
recommendations increased). Among most retained
guideline recommendations, the COR and LOE
increased (Online Table 3).
STUDY LIMITATIONS. We only examined the ﬁnal
published guidelines that changed during the study
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The ACC and the
AHA are adopting more evidence-based and scientiﬁcally robust
approaches to clinical practice guideline development, with
fewer recommendations founded on lower quality evidence or
expert consensus.
TRANSLATIONAL OUTLOOK: Validated methods are needed
toobjectivelyevaluate thequalityofclinicalevidenceandassess the
impact of changes in guideline development on clinical outcomes.
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2733period and did not have information on the de-
liberations that went into the development of each
document. The reason for changes in individual rec-
ommendations was often not explicitly stated in
the updated guidelines. In addition, LOE was
increased in some recommendations on the basis of
evidence from older studies.
CONCLUSIONS
Clinical guideline documents support the delivery of
outstanding, timely, and evidence-based clinical
care. Our analysis suggests that the ACC/AHA guide-
lines underwent substantial revisions with each
update, with signiﬁcant reduction in the number of
recommendations, coupled with a decrease in Class I
and III and LOE: C recommendations. Hence, the
guidelines are becoming more evidence based and
scientiﬁcally robust. The largest proportion of rec-
ommendations, however, is still based on lower levels
of evidence or expert opinion. Although these lower
levels of evidence remain of clinical importance, they
also highlight the need for additional research toimprove the evidence on which clinical guidelines
are built.
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